Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.COV2.S vaccine for prevention of COVID-19 in adults
ISRCTN14722499Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ad26.COV2.S with Placebo (2 arms). Primary endpoint: First occurrence of molecularly confirmed moderate to severe/critical COVID-19 in baseline seronegative participants from 14 days after second vaccination. Started Nov 2020; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN14722499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14722499.